
Galmed buys Colospan with $800K extra cash
- Galmed Pharmaceuticals finalized its acquisition of medical device company Colospan.
- Following the restructured transaction terms, the company's stock fell to 0.58 dollars.
- The buyout gives the company immediate commercial access to European colorectal device markets.
Galmed Pharmaceuticals (NASDAQ:GLMD) closed its Colospan acquisition, gaining a device tested on 97 patients.
This structural adjustment alters the initial terms that both companies originally negotiated earlier this year.
Restructured terms replace a $2M share issuance with an $800K cash payment.
The agreement includes an up-to-$2M tiered earnout scheduled to begin in Q3 2027.
Following the announcement, Galmed Pharmaceuticals' share price was down at $0.58.
The acquired CG-100 device is commercial-ready in Israel and the EU with a German code.
The company stated that the clinical technology may generate its first commercial revenues during 2026.
More from United States
InPost acquisition completed as consortium takes full ownership
Oil prices rise as Middle East supply risks return
TDH Holdings swings to $8.34 million loss
Blue Moon Metals acquires Turner deposit for $4.7 million
Williams-Sonoma revenue rallies 5.8% to $1.99 billion
Newegg returns to profit as Q3 sales rise 15%